Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2007

View Archived Issues

Gilead Sciences reports progress of first quarter

Phase III studies show efficacy and safety of ferumoxytol iron replacement therapy

Recent GSK patent divulges novel therapeutic agent for atopic dermatitis

Improvements seen in type 2 diabetes patients given liraglutide

Etravirine demonstrates short-term efficacy in resistant HIV-1 infection

AstraZeneca to acquire MedImmune

Daiichi Sankyo to transfer all Daiichi Fine Chemical shares to Kyowa Hakko

Novel treatment options for HCV infection reported in recent GSK patents

Japanese submission for Glufast in combination with insulin sensitizer

R3 antibody shows efficacy in pancreatic cancer model

Phase IIa biomarker study investigates HF-0220 in mild to moderate Alzheimer's

Pharmion advances oral azacitidine in phase I

Actavis completes acquisition of Abrika

Enrollment completed in phase III study of Cerepro

Recent 3M and Obihiro University patents disclose new antiinfective agents

GGTase I inhibitor and prodrug profiled at AACR annual meeting

In vivo antitumor activity of novel anti-IGF-1R antibody reported by Schering-Plough

Nippon Shinyaku discontinues development of NS-9

FDA accepts Xcytrin NDA for filing

Approvable letter for bazedoxifene in prevention of postmenopausal osteoporosis

Maraviroc recommended for accelerated approval

Roche files Avastin and Xeloda submissions in Europe

New phase I trial studies NPI-0052 in multiple myeloma

Synosia in-licenses rufinamide for anxiety disorders and bipolar mood disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...